Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well cisplatin, docetaxel, and pembrolizumab work in treating
patients with stage II-III laryngeal cancer. Drugs used in chemotherapy, such as cisplatin
and docetaxel, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy
with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack
the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving
cisplatin, docetaxel, and pembrolizumab may help to control the disease.